AdaptHealth (NASDAQ:AHCO – Get Rating) had its target price upped by stock analysts at Truist Financial from $26.00 to $28.00 in a research report issued on Monday, The Fly reports. Truist Financial’s price objective indicates a potential upside of 37.05% from the stock’s current price.
Other research analysts have also recently issued reports about the company. SVB Leerink increased their price target on AdaptHealth from $24.00 to $29.00 and gave the company an “outperform” rating in a research note on Wednesday, August 10th. Deutsche Bank Aktiengesellschaft increased their price target on AdaptHealth from $22.00 to $26.00 in a research note on Wednesday, August 10th. Finally, TheStreet upgraded AdaptHealth from a “d+” rating to a “c-” rating in a research note on Tuesday, August 2nd. Four research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, AdaptHealth has an average rating of “Buy” and a consensus target price of $26.83.
AdaptHealth Price Performance
AdaptHealth stock opened at $20.43 on Monday. AdaptHealth has a 12 month low of $11.40 and a 12 month high of $28.75. The stock’s 50 day moving average is $20.80 and its 200-day moving average is $18.00. The company has a current ratio of 1.39, a quick ratio of 1.15 and a debt-to-equity ratio of 1.02. The company has a market capitalization of $2.74 billion, a price-to-earnings ratio of 38.75, a PEG ratio of 0.32 and a beta of 0.59.
AdaptHealth (NASDAQ:AHCO – Get Rating) last issued its quarterly earnings results on Tuesday, August 9th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.23). The company had revenue of $727.61 million during the quarter, compared to the consensus estimate of $724.27 million. AdaptHealth had a net margin of 4.91% and a return on equity of 6.49%. The company’s quarterly revenue was up 17.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.11) earnings per share. Equities research analysts expect that AdaptHealth will post 1.37 EPS for the current year.
Insider Transactions at AdaptHealth
In other AdaptHealth news, major shareholder Everest Hill Group Inc. sold 215,382 shares of the business’s stock in a transaction on Friday, August 12th. The shares were sold at an average price of $23.50, for a total value of $5,061,477.00. Following the completion of the sale, the insider now directly owns 15,119,834 shares of the company’s stock, valued at $355,316,099. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, major shareholder Everest Hill Group Inc. sold 215,382 shares of the business’s stock in a transaction dated Friday, August 12th. The shares were sold at an average price of $23.50, for a total transaction of $5,061,477.00. Following the transaction, the insider now owns 15,119,834 shares in the company, valued at $355,316,099. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Christopher J. Joyce sold 100,000 shares of the business’s stock in a transaction dated Tuesday, August 16th. The shares were sold at an average price of $22.20, for a total transaction of $2,220,000.00. Following the transaction, the general counsel now owns 106,071 shares in the company, valued at approximately $2,354,776.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 474,382 shares of company stock valued at $10,938,477. Insiders own 17.29% of the company’s stock.
Institutional Investors Weigh In On AdaptHealth
Institutional investors have recently made changes to their positions in the company. Nisa Investment Advisors LLC lifted its stake in shares of AdaptHealth by 96.6% in the 1st quarter. Nisa Investment Advisors LLC now owns 1,710 shares of the company’s stock valued at $27,000 after purchasing an additional 840 shares during the period. Covestor Ltd purchased a new position in AdaptHealth in the fourth quarter valued at approximately $35,000. US Bancorp DE grew its position in shares of AdaptHealth by 121.7% during the second quarter. US Bancorp DE now owns 2,614 shares of the company’s stock worth $48,000 after acquiring an additional 1,435 shares during the last quarter. Group One Trading L.P. grew its position in shares of AdaptHealth by 134.3% during the first quarter. Group One Trading L.P. now owns 3,720 shares of the company’s stock worth $60,000 after acquiring an additional 2,132 shares during the last quarter. Finally, Advisor Group Holdings Inc. lifted its holdings in shares of AdaptHealth by 306.5% during the fourth quarter. Advisor Group Holdings Inc. now owns 3,000 shares of the company’s stock worth $73,000 after purchasing an additional 2,262 shares during the period. Institutional investors own 75.76% of the company’s stock.
About AdaptHealth
AdaptHealth Corp., together with its subsidiaries, provides home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps to patients for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AdaptHealth, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and AdaptHealth wasn’t on the list.
While AdaptHealth currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com
